Different relevance of inactivation and F468 residue in the mechanisms of hEag1 
channel blockage by astemizole, imipramine and dofetilide

Gomez-Varela, D.; Contreras-Jurado, C.; Furini, S.; Garcia-Ferreiro, R.; Stuhmer, W.; Pardo, L. A.

doi:10.1016/j.febslet.2006.08.030

Datensatz

DATENSATZ AKTIONENEXPORT

Zur Ablage hinzufügen

Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben

Zeitschriftenartikel

Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide

MPG-Autoren

Gomez-Varela, D.
Max Planck Society;

Contreras-Jurado, C.
Max Planck Society;

Furini, S.
Max Planck Society;

Garcia-Ferreiro, R.
Max Planck Society;

Stuhmer, W.
Max Planck Society;

Pardo, L. A.
Max Planck Society;

Externe Ressourcen

https://www.ncbi.nlm.nih.gov/pubmed/16949586
(beliebiger Volltext)

Volltexte (beschränkter Zugriff)

Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.

Volltexte (frei zugänglich)

Es sind keine frei zugänglichen Volltexte in PuRe verfügbar

Ergänzendes Material (frei zugänglich)

Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar

Zitation

Gomez-Varela, D., Contreras-Jurado, C., Furini, S., Garcia-Ferreiro, R., Stuhmer, W., & Pardo, L. A. (2006). Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide. FEBS Lett, 580(21), 5059-66. doi:10.1016/j.febslet.2006.08.030.

Zitierlink: https://hdl.handle.net/21.11116/0000-0009-F221-0

Zusammenfassung

The relevance of a point mutation at the C-terminal end of the S6 helix (F468) and the introduction of C-type inactivation in the blockage of hEag1 channels by astemizole, imipramine and dofetilide was tested. C-type inactivation decreased block by astemizole and dofetilide but not imipramine, suggesting different binding sites in the channel. F468C mutation increased IC(50) for astemizole and imipramine but in contrast to HERG channels, only slightly for dofetilide. Together with measurements on recovery of blocking, our observations indicate that the mechanism of hEag1 blockage by each of these drugs is different, and suggest relevant structural differences between hEag1 and HERG channels.